This prospective, multicenter study is intended to establish the efficacy and toxicity of
treating unresectable colorectal liver metastases with accurately administered radiation
using the CyberKnife stereotactic radiosurgery system.
Radiation: CyberKnife SBRT
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT01318447
Ages eligible for Study
18 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Male or Female
Hepatic metastases from histologically confirmed colorectal adenocarcinoma
3 hepatic lesions or less present
Cumulative size of hepatic lesions between 1 and 10 cm
Treatment determined by the liver/GI tumor board or equivalent organization at the participating site
Metastatic disease not amenable to surgery as assessed by the panel (including a surgeon) or patient who refuses surgery
Patient must be able to undergo contrast enhanced CT for planning
Age >= 18 years old
Performance Status (ECOG) ≤ 2
Minimum of 6 months between the initial diagnosis of the disease and the first hepatic metastasis
Minimum of 4 weeks between prior chemotherapy or targeted therapy and the first CyberKnife session
Total bilirubin ≤ 3 times the upper limit of normal, ASAT and ALAT ≤ 5 times the upper limit of normal
Albumin >= 36 g/L and lymphocytes >= 700/mm3
No contraindication to fiducials implantation, hemostasis problems shall be corrected before implantation
Life expectancy >= 3 months
Patient affiliated with a health insurance system. Applicable for French patients only.
Patient having signed the informed consent
Prior abdominal radiation therapy
Any evidence of visible intra-hepatic bile duct dilatation on pre-treatment images
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.